Non-Stimulant ADHD Medication in India

A shorter menu than the guidelines assume

International guidance was written for pharmacies that stock more than ours do. Both the Indian Psychiatric Society guideline and a 2024 review of ADHD prescribing across Asia record that guanfacine, in any formulation, and extended-release clonidine are not available in India. Only immediate-release clonidine is sold here, which is why Indian dosing is split across the day.

Much of the English-language ADHD material patients read is written in countries where guanfacine is a routine option. Asking for it here is a common and entirely reasonable source of frustration.

The one with the strongest evidence

Atomoxetine increases available noradrenaline by blocking its reuptake. It is not a stimulant, it is not a controlled substance, and it does not produce a noticeable dose-by-dose effect.

In adults it performs better than most people expect. In the largest network meta-analysis, atomoxetine and methylphenidate were statistically indistinguishable on clinician-rated core symptoms in adults, though amphetamines, which are unavailable here, remained clearly superior. A 2025 analysis of adult ADHD interventions found stimulants and atomoxetine were the only treatments showing benefit on both self-rated and clinician-rated measures. In children the gap is wider and methylphenidate is clearly ahead.

The timing is the part most often misunderstood. Pooled adult data show atomoxetine separating from placebo within the first week, but continuing to improve for months, with effect sizes still rising at twenty-six weeks. Judging it at two weeks and abandoning it is the commonest way this medicine fails.

Two warnings, both worth understanding properly

Atomoxetine carries a warning about suicidal ideation. The basis is a pooled analysis of twelve short-term trials in which suicidal ideation was reported by 0.4 per cent of those taking atomoxetine and none of those on placebo. No suicides occurred in any of those trials. The correct response is closer review in the first weeks and after dose changes, particularly in young people, not avoidance of the drug.

It also carries a warning about liver injury. No liver injury was detected across roughly six thousand trial participants; severe cases are rare reports from post-marketing use, usually within the first four months. The product labelling directs testing liver enzymes at the first sign of trouble, such as jaundice, dark urine, unexplained flu-like illness or right upper abdominal tenderness, rather than routine screening bloods. Indian guidance is somewhat more conservative and suggests periodic monitoring, which is a reasonable local practice.

Atomoxetine also raises blood pressure and heart rate in a meaningful minority of people, so both should be measured before starting and rechecked afterwards.

Sedating, useful, and thinly evidenced in adults

Clonidine is an alpha-2 adrenergic agonist. In children its clinician-rated effect in the network meta-analysis was numerically the largest of the non-stimulants. In adults the position is very different: that same analysis found no randomised trials of clonidine or guanfacine in adults at all. Adult use is therefore an extrapolation, and should be described as one.

Sedation is the defining side effect and is often the reason it is chosen, particularly where sleep onset is badly delayed or where a stimulant has worsened tics. Blood pressure and heart rate must be checked before starting, after each increase, and periodically thereafter.

One point is non-negotiable: clonidine must not be stopped abruptly. Stopping suddenly can cause rebound hypertension. Reductions should be gradual and planned with the prescriber, not improvised when a strip runs out.

Off-label, sometimes a sensible third option

Bupropion is licensed for depression and smoking cessation, not for ADHD, and the Indian guideline places it third line. The Cochrane review of six randomised trials in 438 adults found low-quality evidence of benefit on symptom severity and clinical improvement, with withdrawal for adverse effects similar to placebo. The authors were explicit that further research is very likely to change those estimates.

Seizure risk is the constraint that matters. It is dose related, and the risk rises steeply above 450 mg a day. It should not be used by anyone with a seizure disorder, with current or past bulimia or anorexia nervosa, or during abrupt withdrawal from alcohol or sedatives.

Where it can be a reasonable choice is when depression and ADHD sit together and one medicine can address both, which in Indian practice is a common situation.

Not always the second option

Guidance generally puts stimulants first, but there are situations where a non-stimulant is the better opening move rather than a fallback.

That last point carries real weight in India. Atomoxetine is not a controlled substance, has shown no pattern of abuse or euphoriant effect in testing, and produced no withdrawal syndrome on stopping in clinical trials.

What a teleconsultation can and cannot do

This is where the Indian rules genuinely change the answer. Under the Telemedicine Practice Guidelines, drugs listed under Schedule X or the NDPS Act sit on the prohibited list and cannot be prescribed in a teleconsultation at any stage. Methylphenidate is one of them.

The non-stimulants sit differently. The telepsychiatry operational guidelines developed by NIMHANS with the Indian Psychiatric Society place anti-ADHD drugs including atomoxetine and clonidine in List B, which permits teleprescription at a follow-up consultation where the same condition has already been seen in person. In practice that means a first-ever consultation should not end in a prescription for ADHD medication of any kind, and that ongoing non-stimulant treatment can reasonably be reviewed and continued online.

A service offering to start you on ADHD medication entirely online, on a first appointment, is not following Indian rules. Our article on ADHD medication in India covers the prescription rules in more depth.

What should be checked, and how often

Before starting any ADHD medicine, guidance asks for a medical history, a review of everything else you take, height and weight, and a baseline pulse and blood pressure. An ECG is not routinely needed unless there are specific cardiac features in the history or examination.

Afterwards, heart rate and blood pressure should be checked before and after each dose change and at least every six months, weight monitored if it is changing, and sleep reviewed. Treatment should be looked at properly by someone with ADHD expertise at least once a year, including whether it is still needed.

A network meta-analysis of 102 randomised trials found that all ADHD medicines produce small effects on blood pressure and heart rate, with no meaningful separation between stimulants and non-stimulants. The monitoring is not a stimulant-specific formality.